Results 131 to 140 of about 4,022 (166)

Evolution of Cefiderocol Non-Susceptibility inPseudomonas aeruginosain a Patient Without Previous Exposure to the Antibiotic

Clinical Infectious Diseases, 2021
Ana Paula Streling, William Lainhart, Ayesha Khan   +2 more
exaly  

Rapid Development of Cefiderocol Resistance in Carbapenem-resistant Enterobacter cloacae During Therapy Is Associated With Heterogeneous Mutations in the Catecholate Siderophore Receptor cirA

Clinical Infectious Diseases, 2022
Sabrina Klein, Sébastien Boutin, Kaan Kocer   +2 more
exaly  

Defining Baseline Mechanisms of Cefiderocol Resistance in the Enterobacterales

Microbial Drug Resistance, 2022
Patricia J Simner, Yehudit Bergman, Andreas E POSCH   +2 more
exaly  

Cefiderocol in context

The Lancet Infectious Diseases, 2018
openaire   +4 more sources

Cross-resistance to cefiderocol and ceftazidime–avibactam in KPC β-lactamase mutants and the inoculum effect

Clinical Microbiology and Infection, 2021
Claire Amaris Hobson, Hervé Jacquier, Melanie Magnan   +2 more
exaly  

Cefiderocol

Reactions Weekly, 2020
openaire   +1 more source

Cefiderocol/colistin

Reactions Weekly, 2023
openaire   +1 more source

Catecholate siderophore receptor CirA impacts cefiderocol susceptibility in Klebsiella pneumoniae

International Journal of Antimicrobial Agents, 2022
Xueqing Wu, Yunsong Yu, Jian-Cang Zhou   +2 more
exaly  

Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials

Microbial Drug Resistance, 2022
Patrice Nordmann, Ryan K Shields, Yohei Doi   +2 more
exaly  

Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase–Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies

Clinical Infectious Diseases, 2022
Jean-François Timsit, Mical Paul, Ryan K Shields   +2 more
exaly